3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
7
Oxaliplatin
6
Nivolumab
5
Leucovorin
5
fludarabine
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Capecitabine
4
zimberelimab
3
pembrolizumab
3
aldesleukin
3
Trastuzumab
3
Ramucirumab
3
ulixertinib
2
trastuzumab deruxtecan
2
fludarabine phosphate
2
Specimen Handling
2
Irinotecan
2
Cisplatin
2
zolbetuximab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
tislelizumab
1
sodium propionate
1
sapanisertib
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
quemliclustat
×
30 days
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled